Request a representative visit or G7 15 Day or G7 samples
Key CGM Recommendation from ADA 2026 SOC
Overview of key continuous glucose monitoring (CGM) guidance outlined in the 2026 ADA Standards of Care for diabetes to guide clinicians in optimizing patient outcomes with CGM technology.
Background
The 2026 ADA Standards of Care reinforce the role of CGM across a broad range of people with diabetes, including those using insulin therapy, individuals at risk for hypoglycemia, children, older adults, and pregnant individuals with type 1 diabetes. The updates highlight opportunities to incorporate CGM earlier and more consistently throughout the diabetes care journey.
Main outcomes
- ADA expanded recommendations supporting CGM use at diabetes onset and throughout treatment when it can help inform management decisions.
- New and updated guidance emphasizes CGM use in pediatrics, older adults, pregnancy, and for individuals at high risk for hypoglycemia.
- The Standards also encourage consistent CGM use, uninterrupted access to supplies, and consideration of early CGM and AID initiation based on individual needs and preferences.
What this means for your practice
- Consider CGM early in the care journey and across a wider range of patients who may benefit from glucose insights.
- Use the updated recommendations to support CGM discussions with pediatric, pregnant, older adult, and hypoglycemia-prone populations.
References
American Diabetes Association Professional Practice Committee for Diabetes* . 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S150-S165. doi:10.2337/dc26-S007
For a deeper dive on this topic, visit GlucoseTech
